FX.co ★ Henry Schein To Buy Continuous Glucose Monitors Supplier Acentus

Henry Schein, Inc. (HSIC), a leading healthcare solutions provider to dental and medical professionals, has announced its agreement to acquire Acentus, a specialized medical supplier known for its focus on delivering Continuous Glucose Monitors (CGMs).

The financial details of the acquisition, which is expected to be finalized in the first quarter of 2025, have not been disclosed.

Henry Schein anticipates that the acquisition will have a neutral impact on its adjusted earnings per share for 2024 and will enhance earnings beyond that point.

Acentus currently generates annual revenues of approximately $35 million. Following the acquisition, Henry Schein's homecare medical products platform is projected to rise to an annual revenue base of around $350 million.

Stanley Bergman, CEO of Henry Schein, stated: "By incorporating Acentus into our operations, we will fortify our national standing in the home medical supply market and improve our service to valued customers, which include clinics, physician practices, and health systems..."

After the transaction, Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join the Henry Schein team.